Patents of a revolutionizing biotech, G+FLAS Life Sciences
G+FLAS Life Sciences, established in 2014, is a biotech venture company based in Korea that has demonstrated technological excellence in various areas. Some key highlights of G+FLAS's technological achievements include:
Pioneering CRISPR-Cas Genome Editing:
- G+FLAS has developed chimeric genome engineering molecules and novel CRISPR-associated proteins, such as mgCas12a, for precise genome editing.
- Our innovative methods and technologies utilizing CRISPR PLUS and mgCas12a demonstrate our expertise in advanced genome editing techniques.
Cutting-Edge Plant-Derived Biopharmaceuticals:
- G+FLAS has made significant advancements in producing plant-derived biopharmaceuticals using Nicotiana benthamiana plants.
- By deleting protein glycosyltransferases, we have achieved enhanced protein expression and glycan modification, offering potential therapeutic breakthroughs.
Unique Provitamin D3 Tomato Seeds :
- G+FLAS has developed Provitamin D3 tomato seeds, a remarkable achievement as Provitamin D3 is not naturally found in tomatoes or other crops.
- This innovation showcases our ability to design and engineer crops for enhanced nutritional value, opening possibilities for improved food production.
Novel Methods for Genome Editing in Plants :
- G+FLAS has developed efficient DNA-free genome editing methods for plant protoplasts, allowing for high-efficiency production of genome-modified plants.
- Our expertise in this area highlights our commitment to advancing plant genetic engineering techniques for sustainable agriculture.
Advanced Plant Growth Systems :
- G+FLAS has also patented innovative systems for controlling the environment and conditions in closed factories for growing plants.
- Our cutting-edge technologies for temperature/humidity control, dust control, air-conditioning, and plant vacuum infiltration demonstrate our comprehensive approach to plant cultivation.
These patents reflect the technological excellence and innovative spirit of G+FLAS Life Sciences, positioning us as a leading biotech venture company at the forefront of CRISPR-Cas genome editing, plant-derived biopharmaceuticals, and advanced plant growth systems.
Intellectual Properties of G+FLAS Life Sciences, Inc.